Takeda Pharma and 3 other cos submit joint application to Japan min

By Admin
Takeda Pharmaceutical Company Limited, AstraZeneca KK, Mitsubishi Tanabe Pharma Corporation and Eisai Co. Ltd have submitted a joint application to Jap...

Takeda Pharmaceutical Company Limited, AstraZeneca KK, Mitsubishi Tanabe Pharma Corporation and Eisai Co. Ltd have submitted a joint application to Japan’s ministry of Health, Labour and Welfare seeking approval of Helicobacter pylori gastritis.

This is like an additional indication for H. pylori eradication by concomitant therapy with four proton pump inhibitors iansonprazole, omeprazole, rabeprazole sodium and esomeprazole magnesium hydrate.

These pump inhibitors are manufactured and marketed by four companies in Japan under five brand names. The concomitant therapy includes a proton pump inhibitor, amoxicillin hydrate and either clarithromycin or metronidazole.

H.pylori gastritis is also known as chronic active gastritis due to the fact that it is causes histological gastric mucosal injury as a result of persistent infiltration of inflammatory cells in the gastric mucosa due to H.pylori infection.

Under the Japanese National Health Insurance system, the approved indications to eradicate H. pylori are presently limited to gastric and duodenalulcers, gastric MALTlymphoma, idiopathic thrombocytopenic purpura, and stomach after endoscopic resection of early stage gastric cancer, the news reports said.

The four companies expect that once approved, the additional indication will significantly contribute to the prevention and treatment of diseases pertaining to H. pylori.

Takeda is a research-based global company having its main focus on pharmaceuticals. It is the largest pharmaceutical company in Japan and is also a global leader of the industry.

Share
Share

Featured Articles

Cancer Vaccines Breakthrough a Glimpse of Healthcare Future

As the UK's NHS becomes the first healthcare provider to launch a cancer vaccine testing programme, we explore this groundbreaking oncological treatment

Change Healthcare Cyberattack Fallout Continues

Three months on, the cyberattack on UnitedHealth Group's Change Healthcare is still affecting US citizens, with delays and

McKinsey: National E-health Initiatives on the Rise

McKinsey report on countries that are scaling national e-health programmes says it is easing financial pressures on healthcare systems globally

Edwards Lifesciences: a Profile of the Heart Tech Specialist

Medical Devices & Pharma

London Hospitals Cyberattack Wreaks Healthcare Havoc

Technology & AI

Healthcare Provision in India: Challenges and Opportunities

Health Insurance & Finance